CrownBio's 1+1 Mouse Trial
HuScreen+ is the first commercial in vivo screening platform to utilize a 1+1 study design to evaluate drug response using an extensive, well-characterized, clinically relevant patient-derived xenograft (PDX) collection. This exclusive 1+1 study design provides highly reproducible results, and clinically translatable data, to inform on targeted agent and combination therapy treatment approaches in a cost effective manner across a selection of different tumor types.
Highlights of HuScreen+
- Fast and efficient in vivo screening platform
- Under 6-month turnaround time, utilizing live PDX models with proven robust growth
- Reliable 1+1 study design enabling a cost effective way to screen many tumor types
- Wide spectrum of tumor types with unique mutations, genetic features, and drug responses